Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Biol Pharm Bull ; 46(8): 1032-1040, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37532554

RESUMEN

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms and neuropathological features, such as loss of dopaminergic neurons in the substantia nigra pars compacta and accumulation of alpha-synuclein (α-Syn). Progranulin (PGRN) is a secreted growth factor that exhibits anti-inflammatory properties and regulates lysosomal function. Although autophagy-lysosome pathway is the main degradative pathway for α-Syn, the molecular mechanistic relationship between PD and PGRN remains unclear. In this study, we investigated the role of PGRN in PD pathology. PGRN protein expression in striatum was increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model mice. Intracerebroventricular (i.c.v.) administration of PGRN ameliorated the decrease in expression of tyrosine hydroxylase, a dopaminergic neuron marker, in MPTP-treated mice. Furthermore, i.c.v. administration of PGRN ameliorated 6-hydroxydopamine-induced motor deficits. In SH-SY5Y human neuroblastoma cells, 1-methyl-4-phenylpyridinium ion (MPP+), an active metabolite of MPTP, increased α-Syn expression. In contrast, PGRN ameliorated MPP+-induced increase in α-Syn expression. Although PGRN decreased the levels of autophagy-related proteins Sequestosome-1 (p62) and MAP1LC3 (LC3)-II, PGRN did not influence the phosphorylation of AMP-activated protein kinase and mechanistic target of rapamycin, which are also proteins that regulate autophagy. Immunostaining analysis showed that PGRN ameliorated MPP+-induced increase of LC3 puncta, indicator of autophagosome, and co-localization of LC3 and α-Syn. The DALGreen assay showed that PGRN ameliorated MPP+-induced decreasing trend of autolysosomes. These results suggest that PGRN participates in α-Syn degradation via acceleration of the autophagy-lysosome pathway and is a potential therapeutic target for PD.


Asunto(s)
Neuroblastoma , Enfermedad de Parkinson , Animales , Humanos , Ratones , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/efectos adversos , alfa-Sinucleína/metabolismo , Modelos Animales de Enfermedad , Neuronas Dopaminérgicas/metabolismo , Lisosomas/metabolismo , Ratones Endogámicos C57BL , Neuroblastoma/metabolismo , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/metabolismo , Progranulinas/metabolismo
2.
Exp Brain Res ; 240(7-8): 2051-2060, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35587282

RESUMEN

VGF nerve growth factor inducible (VGF) is a neuropeptide precursor, which is induced by several neurotrophic factors, including nerve growth factor and brain-derived neurotrophic factor. Clinically, an upregulation of VGF levels has been reported in the cerebrospinal fluid and prefrontal cortex of patients with schizophrenia. In our previous study, mice overexpressing VGF exhibited schizophrenia-related behaviors. In the current study, we characterized the biochemical changes in the brains of VGF-overexpressing mice. Metabolomics analysis of neurotransmitters revealed that glutamic acid and N-acetyl-L-aspartic acid were increased in the striatum of VGF-overexpressing mice. Additionally, the present study revealed that MK-801, which causes the disturbance in glutamic acid metabolism, increased the expression level of VGF-derived peptide (NAPP129, named VGF20), and VGF-overexpressing mice had higher sensitivity to MK-801. These results suggest that VGF may modulate the regulation of glutamic acid levels and the degree of glutamic acid signaling.


Asunto(s)
Maleato de Dizocilpina , Esquizofrenia , Animales , Maleato de Dizocilpina/farmacología , Ácido Glutámico , Ratones , Fenotipo , Corteza Prefrontal/metabolismo , Esquizofrenia/genética
3.
J Pharmacol Sci ; 148(1): 162-171, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34924122

RESUMEN

Alzheimer's disease (AD) is characterized by progressive cognitive decline, and the number of affected individuals has increased worldwide. However, there are no effective treatments for AD. Therefore, it is important to prevent the onset of dementia. Oxidative stress and endoplasmic reticulum (ER) stress are increased in the brains of AD patients, and are postulated to induce neuronal cell death and cognitive dysfunction. In this study, Centella asiatica, a traditional Indian medicinal herb, were fractionated and compared for their protective effects against glutamate and tunicamycin damage. Araliadiol was identified as a component from the fraction with the highest activity. Further, murine hippocampal cells (HT22) were damaged by glutamate, an oxidative stress inducer. C. asiatica and araliadiol suppressed cell death and reactive oxygen species production. HT22 cells were also injured by tunicamycin, an ER stress inducer. C. asiatica and araliadiol prevented cell death by mainly inhibiting PERK phosphorylation; additionally, C. asiatica also suppressed the expression levels of GRP94 and BiP. In Y-maze test, oral administration of araliadiol (10 mg/kg/day) for 7 days ameliorated the arm alternation ratio in mice with scopolamine-induced cognitive impairment. These results suggest that C. asiatica and its active component, araliadiol, have neuroprotective effects, which may prevent cognitive dysfunction.


Asunto(s)
Muerte Celular/efectos de los fármacos , Centella/química , Disfunción Cognitiva/tratamiento farmacológico , Disfunción Cognitiva/etiología , Disfunción Cognitiva/prevención & control , Neuronas/efectos de los fármacos , Neuronas/patología , Fármacos Neuroprotectores , Fitoterapia , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Triterpenos/administración & dosificación , Triterpenos/farmacología , Administración Oral , Animales , Células Cultivadas , Chaperón BiP del Retículo Endoplásmico/metabolismo , Estrés del Retículo Endoplásmico , Hipocampo/citología , Hipocampo/patología , Masculino , Glicoproteínas de Membrana/metabolismo , Ratones Endogámicos ICR , Estrés Oxidativo/efectos de los fármacos , Fosforilación/efectos de los fármacos , Extractos Vegetales/aislamiento & purificación , Especies Reactivas de Oxígeno/metabolismo , Triterpenos/aislamiento & purificación , eIF-2 Quinasa/metabolismo
4.
J Stroke Cerebrovasc Dis ; 30(9): 105952, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34214963

RESUMEN

OBJECTIVE: Cerebral Blood Flow (CBF) change after Subarachnoid Hemorrhage (SAH) is strongly associated with brain injuries such as early brain injury and delayed cerebral ischemia. We evaluated the correlation between CBF using Laser Speckle Flow Imaging (LSFI) after SAH and neurological findings in the sub-acute phase. METHOD: An SAH was induced by endovascular perforation in male mice. CBF was quantitatively measured by using LSFI at six time points, immediately to 14 days after SAH induction. Behavior tests and survival rate were evaluated. The mice were divided into recovery and hypo-perfusion groups according to their CBF at 1 day after the procedure. RESULT: Forty mice were included in this study. Five mice (20%) were included in the hypo-perfusion group, and the remaining 20 (80%) mice were classified as the recovery group. The decrease of CBF in the recovery group was observed until 1 day after the procedure. However, the decrease of CBF in the hypo-perfusion group was prolonged until 7 days after the procedure. Neurological findings and survival rates in the hypo-perfusion group were significantly worse than those in the recovery group. The low alternation cases (≤ 50%) in the Y-maze test in the recovery group (n = 5) had significantly lower CBF at 1 day after the procedure. CONCLUSION: Low blood flow at 1 day after SAH was associated with worse survival rate, neurological findings, and memory disturbance. Early improvement in CBF may be associated with an improved prognosis after SAH.


Asunto(s)
Conducta Animal , Encéfalo/irrigación sanguínea , Circulación Cerebrovascular , Trastornos de la Memoria/fisiopatología , Memoria , Hemorragia Subaracnoidea/fisiopatología , Animales , Velocidad del Flujo Sanguíneo , Cognición , Modelos Animales de Enfermedad , Imágenes de Contraste de Punto Láser , Masculino , Aprendizaje por Laberinto , Trastornos de la Memoria/etiología , Trastornos de la Memoria/psicología , Ratones , Imagen de Perfusión , Hemorragia Subaracnoidea/complicaciones , Hemorragia Subaracnoidea/psicología , Factores de Tiempo
5.
Mar Drugs ; 18(9)2020 Sep 18.
Artículo en Inglés | MEDLINE | ID: mdl-32962073

RESUMEN

Several antitumour drugs have been isolated from natural products and many clinical trials are underway to evaluate their potential. There have been numerous reports about the antitumour effects of astaxanthin against several tumours but no studies into its effects against glioblastoma. Astaxanthin is a red pigment found in crustaceans and fish and is also synthesized in Haematococcus pluvialis; adonixanthin is an intermediate product of astaxanthin. It is known that both astaxanthin and adonixanthin possess radical scavenging activity and can confer a protective effect on several damages. In this study, we clarified the antitumour effects of astaxanthin and adonixanthin using glioblastoma models. Specifically, astaxanthin and adonixanthin showed an ability to suppress cell proliferation and migration in three types of glioblastoma cells. Furthermore, these compounds were confirmed to transfer to the brain in a murine model. In the murine orthotopic glioblastoma model, glioblastoma progression was suppressed by the oral administration of astaxanthin and adonixanthin at 10 and 30 mg/kg, respectively, for 10 days. These results suggest that both astaxanthin and adonixanthin have potential as treatments for glioblastoma.


Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Carotenoides/farmacología , Glioblastoma/tratamiento farmacológico , Administración Oral , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacología , Carotenoides/administración & dosificación , Línea Celular Tumoral , Progresión de la Enfermedad , Glioblastoma/patología , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , Xantófilas/administración & dosificación , Xantófilas/farmacología
6.
Biol Pharm Bull ; 42(7): 1140-1145, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31257290

RESUMEN

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by disabling fatigue of at least 6 months, in addition to symptoms such as muscle pain and muscle weakness. There is no treatment provides long-term benefits to most patients. Recently, clinical research suggested the involvement of pyruvate dehydrogenase (PDH) in ME/CFS. PDH is a crucial enzyme in the mitochondria matrix that links glycolysis to the tricarboxylic acid cycle and oxidative phosphorylation. However, it is little known whether PDH could be a therapeutic target. The purpose of this study was to establish ME/CFS in mice and to investigate the involvement of PDH in ME/CFS. To induce the chronic fatigue in mice, a repeated forced swimming test was conducted. To evaluate fatigue, we measured immobility time in forced swimming test and starting time of grooming. An open field test was conducted on day 8. After 25 d of the forced swimming test, the mitochondrial fraction in gastrocnemius muscle was isolated and PDH activity was measured. Moreover, we evaluated the effect of PDH activation by administering sodium dichloroacetate (DCA). In ME/CFS mice group, the immobility time and starting time of grooming increased time-dependently. In addition, the moved distance was decreased in ME/CFS mice. PDH activity was decreased in the mitochondrial fraction of the gastrocnemius muscle of the forced swimming group. DCA treatment may be beneficial in preventing fatigue-like behavior in ME/CFS. These findings indicate that ME/CFS model was established in mice and that a decrease in mitochondrial PDH activity is involved with the symptom of ME/CFS.


Asunto(s)
Modelos Animales de Enfermedad , Síndrome de Fatiga Crónica/enzimología , Síndrome de Fatiga Crónica/fisiopatología , Cetona Oxidorreductasas/fisiología , Natación , Animales , Conducta Animal , Ácido Dicloroacético/farmacología , Ácido Dicloroacético/uso terapéutico , Síndrome de Fatiga Crónica/tratamiento farmacológico , Masculino , Ratones Endogámicos ICR , Mitocondrias Musculares/fisiología , Músculo Esquelético/fisiología
7.
Biosci Biotechnol Biochem ; 79(11): 1838-44, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26059088

RESUMEN

Huperzia serrata has been used as a Chinese folk medicine for many years. It contains huperzine A, which has a protective effect against memory deficits in animal models; however, it is unclear if H. serrata extract exerts any effects in Alzheimer's disease (AD) models. We used H. serrata collected in Japan and determined its huperzine A content using HPLC. We determined its inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activity. H. serrata extract (30 mg/kg/day) and donepezil (10 mg/kg/day) were orally administrated for 7 days. After repeated administration, we performed the Y-maze and passive avoidance tests. H. serrata extract contained 0.5% huperzine A; H. serrata extract inhibited AChE, but not BuChE. H. serrata extract ameliorated cognitive function in mice. These results indicate that Japanese H. serrata extract ameliorates cognitive function deficits by inhibiting AChE. Therefore, H. serrata extract may be valuable for the prevention or treatment of dementia in AD.


Asunto(s)
Alcaloides/administración & dosificación , Inhibidores de la Colinesterasa/administración & dosificación , Trastornos del Conocimiento/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Sesquiterpenos/administración & dosificación , Acetilcolinesterasa/biosíntesis , Acetilcolinesterasa/efectos de los fármacos , Alcaloides/química , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/patología , Animales , Butirilcolinesterasa/biosíntesis , Butirilcolinesterasa/efectos de los fármacos , Trastornos del Conocimiento/inducido químicamente , Trastornos del Conocimiento/patología , Huperzia/química , Japón , Trastornos de la Memoria/tratamiento farmacológico , Trastornos de la Memoria/patología , Ratones , Extractos Vegetales/química , Escopolamina/toxicidad , Sesquiterpenos/química
8.
Naunyn Schmiedebergs Arch Pharmacol ; 394(1): 73-84, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32808069

RESUMEN

PURPOSE: Intracranial hemorrhage (ICH) is a devastating disease with high mortality and morbidity. After ICH, iron released from the hematoma plays a crucial role in secondary brain injury. Deferasirox (DFR) is a trivalent iron chelator, which was approved to treat iron overload syndrome after transfusion. The aim of the present study was to investigate the protective effects of DFR in both in vitro and in vivo ICH models. METHODS: Using a hemin-induced SH-SY5Y cell damage model, we performed an intracellular bivalent iron (Fe2+) accumulation assay, cell death assay, oxidative stress assessments, and Western blotting analysis. Moreover, the effects of DFR intraventricular administration on hematoma, neurological deficits, and histological alteration were evaluated in an in vivo ICH mouse model by collagenase. RESULTS: DFR significantly suppressed the intracellular Fe2+ accumulation and cell death caused by hemin exposure. These effects were related to the suppression of both reactive oxygen species and lipid peroxidation over-production. In Western blotting analysis, hemin increased the expression of ferritin (an iron storage protein), LC3 and p62 (autophagy-related markers), phosphorylated p38 (a stress response protein), and cleaved-caspase3 and cleaved-poly (adenosine diphosphate ribose) polymerase (PARP) (apoptosis-related makers). However, DFR suppressed the increase of these proteins. In addition, DFR attenuated the neurological deficits until 7 days after ICH without affecting hematoma and injury area. Furthermore, DFR also suppressed microglia/macrophage activation in peri-hematoma area at 3 days after ICH. CONCLUSION: These findings indicate that DFR might be a useful therapeutic agent for the therapy of ICH.


Asunto(s)
Antioxidantes/uso terapéutico , Deferasirox/uso terapéutico , Accidente Cerebrovascular Hemorrágico/tratamiento farmacológico , Quelantes del Hierro/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Animales , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Autofagia/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/patología , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Deferasirox/farmacología , Modelos Animales de Enfermedad , Accidente Cerebrovascular Hemorrágico/patología , Humanos , Hierro/metabolismo , Quelantes del Hierro/farmacología , Masculino , Ratones , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Fármacos Neuroprotectores/farmacología , Especies Reactivas de Oxígeno/metabolismo
9.
Microscopy (Oxf) ; 66(6): 380-387, 2017 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-28992228

RESUMEN

The lath martensite structure contains hierarchical substructures, such as blocks, packets and prior austenite grains. Generally, high-angle grain boundaries in the lath martensite structure, i.e. block boundaries, are correlated to mechanical properties. On the other hand, low-angle grain boundaries play an important role in morphological development. However, it is difficult to understand their nature because of the difficulty associated with the characterization of the complex morphologies by two-dimensional techniques. This study aims to identify the morphologies of low-angle boundaries in ultra-low carbon lath martensite. A serial-sectioning method and electron backscatter diffraction analysis are utilized to reconstruct three-dimensional objects and analyse their grain boundaries. A packet comprizes two low-angle grain boundaries - sub-block and fine packet boundaries. Sub-blocks exhibit porous morphology, with two large sub-blocks predominantly occupying a block. Several fine packets with different habit planes from the surrounding regions are observed. Fine packets are present in blocks, which frequently share a close-packed direction with the neighbouring fine packets. In addition, fine packets are in contact with the sub-block boundaries.

10.
Eur J Pharmacol ; 789: 244-253, 2016 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-27452919

RESUMEN

Crocetin, the aglycone of crocin, is a carotenoid found in fruits of gardenia (Gardeina jasminoides Ellis) and saffron (Crocus sativus L.). We investigated the protective effects of crocetin against ultraviolet-A (UV-A)-induced skin damage and explored the underlying mechanism. Human skin-derived fibroblasts cells (NB1-RGB) were damaged by exposure to UV-A irradiation (10J/cm(2)). Crocetin protected these cells against cell death and reduced the production of reactive oxygen species induced by UV-A irradiation. Crocetin treatment also suppressed induction of caspase-3 activation by UV-A irradiation. The effects of crocetin against oxidative stress were also examined by imaging of Keap1-dependent oxidative stress detector (OKD) mice. UV-A irradiation upregulated oxidative stress in the OKD mice skin, while crocetin administration (100mg/kg, p.o.) ameliorated this oxidative stress. Crocetin administration also decreased lipid peroxidation in the skin. These findings suggest that crocetin its observed protective effects against UV-A induced skin damage by reducing reactive oxygen species production and cell apoptosis.


Asunto(s)
Antioxidantes/farmacología , Carotenoides/farmacología , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/efectos de la radiación , Protectores contra Radiación/farmacología , Piel/citología , Rayos Ultravioleta/efectos adversos , Animales , Autofagia/efectos de los fármacos , Autofagia/efectos de la radiación , Muerte Celular/efectos de los fármacos , Muerte Celular/efectos de la radiación , Crocus/química , Estrés del Retículo Endoplásmico/efectos de los fármacos , Estrés del Retículo Endoplásmico/efectos de la radiación , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/efectos de la radiación , Masculino , Ratones , Especies Reactivas de Oxígeno/metabolismo , Piel/efectos de los fármacos , Piel/metabolismo , Piel/efectos de la radiación , Vitamina A/análogos & derivados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA